GlassScriptPhysician profile
Gregory Dalencourt
NPI 1013185842
$11,794.44
in general payments reported to CMS, 2019-2025
30 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what 79% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $124 · 2021: $4,192 · 2022: $1,619 · 2023: $384 · 2024: $3,437 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,408 · Food and Beverage: $2,227 · Education: $750 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,408.02 |
| Food and Beverage | $2,226.83 |
| Education | $750.00 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baudax Bio INC. | $4,691.00 | 2021-2022 | |
| Intuitive Surgical, INC. | $3,067.71 | 2019-2025 | Da Vinci Surgical System |
| W. L. Gore & Associates, INC. | $1,879.64 | 2024 | Gore Bio-A Tissue Reinforcement, Gore Cardioform Septal Occluder, Gore Synecor Biomaterial |
| Stryker Corporation | $451.25 | 2022 | |
| Novo Nordisk INC | $408.12 | 2019-2024 | Wegovy |
| Abbvie INC. | $152.88 | 2020-2024 | Creon |
| Tela Bio, INC. | $137.98 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Amgen INC. | $132.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.80 | 2024-2025 | Entyvio |
| Medtronic, INC. | $81.41 | 2021-2025 | Transorb |
| Braintree Laboratories, INC. | $71.52 | 2021 | |
| Davol INC. | $69.38 | 2021-2025 | Phasix Mesh |
| Redhill Biopharma INC. | $61.37 | 2021 | |
| Innocoll Pharmaceuticals Limited | $51.84 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $50.87 | 2023 | Seglentis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $48.65 | 2019-2020 | |
| Ethicon US, LLC | $46.07 | 2020 | |
| Baxter Healthcare | $43.56 | 2023-2024 | Tisseel, Perclot |
| Lilly USA, LLC | $27.73 | 2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $27.58 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $24.55 | 2019 | |
| Organogenesis INC. | $22.54 | 2024 | |
| Mauna Kea Technologies, INC. | $21.96 | 2019 | |
| Eagle Pharmaceuticals, INC. | $19.83 | 2022 | |
| Thd America, INC. | $19.72 | 2021-2024 | |
| Daiichi Sankyo INC. | $19.08 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.72 | 2021 | |
| Endo Pharmaceuticals INC. | $14.79 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.76 | 2023 | Caldolor |
| Allergan, INC. | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Dalencourt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.